Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt
Identifieur interne : 002365 ( Istex/Corpus ); précédent : 002364; suivant : 002366Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt
Auteurs : Philip J. Thompson ; Neil L. Misso ; John WoodsSource :
- Respirology [ 1323-7799 ] ; 2007-11.
Abstract
Abstract: Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.
Url:
DOI: 10.1111/j.1440-1843.2007.01017.x
Links to Exploration step
ISTEX:F30D2E183BDBBC35E40562F8BDF850AB2ECC0932Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title><author><name sortKey="Thompson, Philip J" sort="Thompson, Philip J" uniqKey="Thompson P" first="Philip J." last="Thompson">Philip J. Thompson</name><affiliation><mods:affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</mods:affiliation></affiliation></author><author><name sortKey="Misso, Neil L" sort="Misso, Neil L" uniqKey="Misso N" first="Neil L." last="Misso">Neil L. Misso</name><affiliation><mods:affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</mods:affiliation></affiliation></author><author><name sortKey="Woods, John" sort="Woods, John" uniqKey="Woods J" first="John" last="Woods">John Woods</name><affiliation><mods:affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F30D2E183BDBBC35E40562F8BDF850AB2ECC0932</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1440-1843.2007.01017.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-7QGVFDV9-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002365</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002365</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title><author><name sortKey="Thompson, Philip J" sort="Thompson, Philip J" uniqKey="Thompson P" first="Philip J." last="Thompson">Philip J. Thompson</name><affiliation><mods:affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</mods:affiliation></affiliation></author><author><name sortKey="Misso, Neil L" sort="Misso, Neil L" uniqKey="Misso N" first="Neil L." last="Misso">Neil L. Misso</name><affiliation><mods:affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</mods:affiliation></affiliation></author><author><name sortKey="Woods, John" sort="Woods, John" uniqKey="Woods J" first="John" last="Woods">John Woods</name><affiliation><mods:affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Respirology</title><title level="j" type="sub">The Clinical Management of Severe Asthma, Canberra, Australia</title><title level="j" type="alt">RESPIROLOGY</title><idno type="ISSN">1323-7799</idno><idno type="eISSN">1440-1843</idno><imprint><biblScope unit="vol">12</biblScope><biblScope unit="issue">s3</biblScope><biblScope unit="page" from="S29">S29</biblScope><biblScope unit="page" to="S34">S34</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2007-11">2007-11</date></imprint><idno type="ISSN">1323-7799</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1323-7799</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>omalizumab</json:string><json:string>asthma</json:string><json:string>corticosteroid</json:string><json:string>prednisolone</json:string><json:string>allergy</json:string><json:string>cyclosporine</json:string><json:string>steroid</json:string><json:string>respirology</json:string><json:string>allergic asthma</json:string><json:string>asian pacific society</json:string><json:string>oral corticosteroid</json:string><json:string>author journal compilation</json:string><json:string>cochrane database syst</json:string><json:string>allergy clin</json:string><json:string>severe allergic asthma</json:string><json:string>dos</json:string><json:string>western australia</json:string><json:string>oral corticosteroid therapy</json:string><json:string>severe asthma</json:string><json:string>corticosteroid therapy</json:string><json:string>high dos</json:string><json:string>house dust mite</json:string><json:string>asthma therapy</json:string><json:string>diabetes mellitus</json:string><json:string>steroid resistance</json:string><json:string>lung function</json:string><json:string>prednisolone dose</json:string><json:string>such patient</json:string><json:string>therapy fev1</json:string><json:string>prednisolone dose cyclosporine dose</json:string><json:string>normal normal</json:string><json:string>allergic</json:string><json:string>allergen immunotherapy</json:string><json:string>multiple admission</json:string><json:string>molecular mechanism</json:string><json:string>corticosteroid resistance</json:string><json:string>systemic side effect</json:string><json:string>defective binding</json:string><json:string>localized pulmonary steroid resistance</json:string><json:string>other patient</json:string><json:string>glucocorticoid receptor</json:string><json:string>recurrent infection</json:string><json:string>immunosuppressive drug</json:string><json:string>clinical feature</json:string><json:string>corticosteroid dose</json:string><json:string>airway obstruction</json:string><json:string>immunosuppressive agent</json:string></teeft></keywords><author><json:item><name>Philip J. THOMPSON</name><affiliations><json:string>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</json:string></affiliations></json:item><json:item><name>Neil L. MISSO</name><affiliations><json:string>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</json:string></affiliations></json:item><json:item><name>John WOODS</name><affiliations><json:string>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>allergy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>anti‐IgE</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>asthma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>omalizumab</value></json:item></subject><articleId><json:string>RESP1017</json:string></articleId><arkIstex>ark:/67375/WNG-7QGVFDV9-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>caseStudy</json:string></originalGenre><abstract>Abstract: Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.</abstract><qualityIndicators><score>5.588</score><pdfWordCount>2832</pdfWordCount><pdfCharCount>18565</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>595.276 x 779.528 pts</pdfPageSize><pdfWordsPerPage>472</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>63</abstractWordCount><abstractCharCount>400</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title><pmid><json:string>17956517</json:string></pmid><genre><json:string>case-report</json:string></genre><host><title>Respirology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1440-1843</json:string></doi><issn><json:string>1323-7799</json:string></issn><eissn><json:string>1440-1843</json:string></eissn><publisherId><json:string>RESP</json:string></publisherId><volume>12</volume><issue>s3</issue><pages><first>S29</first><last>S34</last><total>6</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2007</json:string></date><geogName></geogName><orgName><json:string>Lung Institute of Western Australia, Ground Floor</json:string><json:string>Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia Omalizumab</json:string><json:string>Sir Charles Gairdner Hospital, Nedlands, WA</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>John Woods</json:string><json:string>Philip J. Thompson</json:string><json:string>Philip Thompson</json:string><json:string>Nil Nil</json:string><json:string>Neil Misso</json:string><json:string>JoB</json:string></persName><placeName><json:string>Australia</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Thompson et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-7QGVFDV9-J</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - respiratory system</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - respiratory system</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pulmonary and Respiratory Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1111/j.1440-1843.2007.01017.x</json:string></doi><id>F30D2E183BDBBC35E40562F8BDF850AB2ECC0932</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7QGVFDV9-J/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7QGVFDV9-J/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-7QGVFDV9-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title><title level="a" type="short">Omalizumab and steroid‐resistant asthma</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2007-11"></date></publicationStmt><notesStmt><note type="content-type" subtype="case-report" source="caseStudy" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-29919SZJ-6">case-report</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="case-report"><analytic><title level="a" type="main">Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title><title level="a" type="short">Omalizumab and steroid‐resistant asthma</title><author xml:id="author-0000"><persName><forename type="first">Philip J.</forename><surname>THOMPSON</surname></persName><affiliation><orgName type="institution">Lung Institute of Western Australia and Centre for Asthma</orgName><orgName type="laboratory">Allergy and Respiratory Research</orgName><orgName type="institution">The University of Western Australia</orgName><address><addrLine>Perth</addrLine><addrLine>Western Australia, Australia</addrLine><country key="AU" xml:lang="en">AUSTRALIA</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Neil L.</forename><surname>MISSO</surname></persName><affiliation><orgName type="institution">Lung Institute of Western Australia and Centre for Asthma</orgName><orgName type="laboratory">Allergy and Respiratory Research</orgName><orgName type="institution">The University of Western Australia</orgName><address><addrLine>Perth</addrLine><addrLine>Western Australia, Australia</addrLine><country key="AU" xml:lang="en">AUSTRALIA</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">John</forename><surname>WOODS</surname></persName><affiliation><orgName type="institution">Lung Institute of Western Australia and Centre for Asthma</orgName><orgName type="laboratory">Allergy and Respiratory Research</orgName><orgName type="institution">The University of Western Australia</orgName><address><addrLine>Perth</addrLine><addrLine>Western Australia, Australia</addrLine><country key="AU" xml:lang="en">AUSTRALIA</country></address></affiliation></author><idno type="istex">F30D2E183BDBBC35E40562F8BDF850AB2ECC0932</idno><idno type="ark">ark:/67375/WNG-7QGVFDV9-J</idno><idno type="DOI">10.1111/j.1440-1843.2007.01017.x</idno><idno type="unit">RESP1017</idno><idno type="toTypesetVersion">file:RESP.RESP1017.pdf</idno></analytic><monogr><title level="j" type="main">Respirology</title><title level="j" type="sub">The Clinical Management of Severe Asthma, Canberra, Australia</title><title level="j" type="alt">RESPIROLOGY</title><idno type="pISSN">1323-7799</idno><idno type="eISSN">1440-1843</idno><idno type="book-DOI">10.1111/(ISSN)1440-1843</idno><idno type="book-part-DOI">10.1111/res.2007.12.issue-s3</idno><idno type="product">RESP</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">12</biblScope><biblScope unit="issue">s3</biblScope><biblScope unit="page" from="S29">S29</biblScope><biblScope unit="page" to="S34">S34</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2007-11"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Abstract: </hi> Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">allergy</term><term xml:id="k2">anti‐IgE</term><term xml:id="k3">asthma</term><term xml:id="k4">omalizumab</term></keywords><keywords rend="tocHeading1"><term>Proceedings of the TSANZ 2006 Novartis Satellite Symposium – The Clinical Management of Severe Asthma</term></keywords><keywords rend="tocHeading2"><term>ORIGINAL ARTICLES</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7QGVFDV9-J/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Asia</publisherName><publisherLoc>Melbourne, Australia</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1440-1843</doi><issn type="print">1323-7799</issn><issn type="electronic">1440-1843</issn><idGroup><id type="product" value="RESP"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="RESPIROLOGY">Respirology</title></titleGroup></publicationMeta><publicationMeta level="part" position="11000"><doi origin="wiley">10.1111/res.2007.12.issue-s3</doi><titleGroup><title type="specialIssueTitle">The Clinical Management of Severe Asthma, Canberra, Australia</title></titleGroup><numberingGroup><numbering type="journalVolume" number="12">12</numbering><numbering type="supplement">s3</numbering></numberingGroup><coverDate startDate="2007-11">November 2007</coverDate></publicationMeta><publicationMeta level="unit" type="caseStudy" position="4" status="forIssue"><doi origin="wiley">10.1111/j.1440-1843.2007.01017.x</doi><idGroup><id type="unit" value="RESP1017"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="tocHeading1">Proceedings of the TSANZ 2006 Novartis Satellite Symposium – The Clinical Management of Severe Asthma</title><title type="tocHeading2">ORIGINAL ARTICLES</title></titleGroup><eventGroup><event type="firstOnline" date="2007-10-18"></event><event type="publishedOnlineFinalForm" date="2007-10-18"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.4 mode:FullText source:FullText result:FullText" date="2010-03-30"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-08"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">S29</numbering><numbering type="pageLast">S34</numbering></numberingGroup><correspondenceTo>Philip J. Thompson, Lung Institute of Western Australia, Ground Floor, E Block, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia. Email: <email>pjthomps@liwa.uwa.edu.au</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:RESP.RESP1017.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="4"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="3380"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title><title type="shortAuthors">PJ Thompson <i>et al.</i></title><title type="short">Omalizumab and steroid‐resistant asthma</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#aff-1-1"><personName><givenNames>Philip J.</givenNames><familyName>THOMPSON</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#aff-1-1"><personName><givenNames>Neil L.</givenNames><familyName>MISSO</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#aff-1-1"><personName><givenNames>John</givenNames><familyName>WOODS</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="AU"><unparsedAffiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">allergy</keyword><keyword xml:id="k2">anti‐IgE</keyword><keyword xml:id="k3">asthma</keyword><keyword xml:id="k4">omalizumab</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><!--
Omalizumab (Xolair) in patients with steroid-resistant asthma: Lessons to be learnt
THOMPSON PJ, MISSO NL, WOODS J. Respirology 2007; 12 (Suppl. 3): S29–S34
--><p><b>Abstract: </b> Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1" numbered="no"><p>Conflict of interest: Philip Thompson has received an honorarium for speaking at this symposium. No conflict of interest has been declared by Neil Misso. No conflict of interest statement has been received from John Woods.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Omalizumab and steroid‐resistant asthma</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt</title></titleInfo><name type="personal"><namePart type="given">Philip J.</namePart><namePart type="family">THOMPSON</namePart><affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Neil L.</namePart><namePart type="family">MISSO</namePart><affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John</namePart><namePart type="family">WOODS</namePart><affiliation>Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="case-report" displayLabel="caseStudy" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-29919SZJ-6">case-report</genre><originInfo><publisher>Blackwell Publishing Asia</publisher><place><placeTerm type="text">Melbourne, Australia</placeTerm></place><dateIssued encoding="w3cdtf">2007-11</dateIssued><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">1</extent><extent unit="tables">4</extent><extent unit="formulas">0</extent><extent unit="references">24</extent><extent unit="linksCrossRef">0</extent><extent unit="words">3380</extent></physicalDescription><abstract lang="en">Abstract: Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.</abstract><subject lang="en"><genre>keywords</genre><topic>allergy</topic><topic>anti‐IgE</topic><topic>asthma</topic><topic>omalizumab</topic></subject><relatedItem type="host"><titleInfo><title>Respirology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1323-7799</identifier><identifier type="eISSN">1440-1843</identifier><identifier type="DOI">10.1111/(ISSN)1440-1843</identifier><identifier type="PublisherID">RESP</identifier><part><date>2007</date><detail type="title"><title>The Clinical Management of Severe Asthma, Canberra, Australia</title></detail><detail type="volume"><caption>vol.</caption><number>12</number></detail><detail type="issue"><caption>Suppl. no.</caption><number>s3</number></detail><extent unit="pages"><start>S29</start><end>S34</end><total>6</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Difficult asthma</title></titleInfo><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Barnes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Woolcock</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barnes PJ, Woolcock AJ. Difficult asthma. Eur. Respir. J. 1998; 12: 1209–18.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>1209</start><end>18</end></extent></part><relatedItem type="host"><titleInfo><title>Eur. Respir. J.</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>1209</start><end>18</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Special issues in asthma III. Corticosteroid resistance</title></titleInfo><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Thompson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Understanding Asthma: A Management Companion.</title></titleInfo><originInfo><publisher>MacLennan & Petty</publisher></originInfo><part><date>2000</date><extent unit="pages"><start>200</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Glucocorticoid resistance in asthma</title></titleInfo><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Barnes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Greening</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GK</namePart><namePart type="family">Crompton</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am. J. Respir. Crit. Care Med. 1995; 152: S125–40.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>S125</start><end>40</end></extent></part><relatedItem type="host"><titleInfo><title>Am. J. Respir. Crit. Care Med.</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>152</number></detail><extent unit="pages"><start>S125</start><end>40</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Corticosteroid‐insensitive asthma: molecular mechanisms</title></titleInfo><name type="personal"><namePart type="given">IM</namePart><namePart type="family">Adcock</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Lane</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Adcock IM, Lane SJ. Corticosteroid‐insensitive asthma: molecular mechanisms. J. Endocrinol. 2003; 178: 347–55.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>178</number></detail><extent unit="pages"><start>347</start><end>55</end></extent></part><relatedItem type="host"><titleInfo><title>J. Endocrinol.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>178</number></detail><extent unit="pages"><start>347</start><end>55</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Steroid resistance in asthma: a major problem requiring novel solutions or a non‐issue?</title></titleInfo><name type="personal"><namePart type="given">IM</namePart><namePart type="family">Adcock</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Ito</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Adcock IM, Ito K. Steroid resistance in asthma: a major problem requiring novel solutions or a non‐issue? Curr. Opin. Pharmacol. 2004; 4: 257–62.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>257</start><end>62</end></extent></part><relatedItem type="host"><titleInfo><title>Curr. Opin. Pharmacol.</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>257</start><end>62</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>The costs of asthma</title></titleInfo><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Barnes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Jonsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Klim</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur. Respir. J. 1996; 9: 636–42.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>636</start><end>42</end></extent></part><relatedItem type="host"><titleInfo><title>Eur. Respir. J.</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>636</start><end>42</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Update on glucocorticoid action and resistance</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Ito</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KF</namePart><namePart type="family">Chung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IM</namePart><namePart type="family">Adcock</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 2006; 117: 522–43.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>117</number></detail><extent unit="pages"><start>522</start><end>43</end></extent></part><relatedItem type="host"><titleInfo><title>J. Allergy Clin. Immunol.</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>117</number></detail><extent unit="pages"><start>522</start><end>43</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Alternate treatments in asthma</title></titleInfo><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Niven</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Argyros</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Niven AS, Argyros G. Alternate treatments in asthma. Chest 2003; 123: 1254–65.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>1254</start><end>65</end></extent></part><relatedItem type="host"><titleInfo><title>Chest</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>1254</start><end>65</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Methotrexate as a steroid sparing agent for asthma in adults</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Davies</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Olson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Gibson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst. Rev. 2000; (2): CD000391.</note><part><date>2000</date><detail type="issue"><caption>no.</caption><number>2</number></detail></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst. Rev.</title></titleInfo><part><date>2000</date><detail type="issue"><caption>no.</caption><number>2</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Azathioprine as an oral corticosteroid sparing agent for asthma</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Dean</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Dewey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Bara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TJ</namePart><namePart type="family">Lasserson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EH</namePart><namePart type="family">Walters</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst. Rev. 2004; (1): CD003270.</note><part><date>2004</date><detail type="issue"><caption>no.</caption><number>1</number></detail></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst. Rev.</title></titleInfo><part><date>2004</date><detail type="issue"><caption>no.</caption><number>1</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Cyclosporin as an oral corticosteroid sparing agent in stable asthma</title></titleInfo><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Evans</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Cullinan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Geddes</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst. Rev. 2001; (2): CD002993.</note><part><date>2001</date><detail type="issue"><caption>no.</caption><number>2</number></detail></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst. Rev.</title></titleInfo><part><date>2001</date><detail type="issue"><caption>no.</caption><number>2</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Allergen immunotherapy for asthma</title></titleInfo><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Abramson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Puy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Weiner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 2003; (4): CD001186.</note><part><date>2003</date><detail type="issue"><caption>no.</caption><number>4</number></detail></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst. Rev.</title></titleInfo><part><date>2003</date><detail type="issue"><caption>no.</caption><number>4</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Cost‐effectiveness analysis of omalizumab in adults and adolescents with moderate‐to‐severe allergic asthma</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Oba</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Salzman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Oba Y, Salzman GA. Cost‐effectiveness analysis of omalizumab in adults and adolescents with moderate‐to‐severe allergic asthma. J. Allergy Clin. Immunol. 2004; 114: 265–9.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>114</number></detail><extent unit="pages"><start>265</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>J. Allergy Clin. Immunol.</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>114</number></detail><extent unit="pages"><start>265</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma</title></titleInfo><name type="personal"><namePart type="given">ST</namePart><namePart type="family">Holgate</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AG</namePart><namePart type="family">Chuchalin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Hebert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Lotvall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GB</namePart><namePart type="family">Persson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB et al. Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 2004; 34: 632–8.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>632</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Exp. Allergy</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>632</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma</title></titleInfo><name type="personal"><namePart type="given">JG</namePart><namePart type="family">Ayres</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Higgins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ER</namePart><namePart type="family">Chilvers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Ayre</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Blogg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Fox</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma. Allergy 2004; 59: 701–8.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>701</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>701</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Omalizumab improves asthma‐related quality of life in patients with severe allergic asthma</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Finn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Gross</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Van Bavel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Windom</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Finn A, Gross G, Van Bavel J, Lee T, Windom H et al. Omalizumab improves asthma‐related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. 2003; 111: 278–84.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>278</start><end>84</end></extent></part><relatedItem type="host"><titleInfo><title>J. Allergy Clin. Immunol.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>278</start><end>84</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Omalizumab is effective in the long‐term control of severe allergic asthma</title></titleInfo><name type="personal"><namePart type="given">BQ</namePart><namePart type="family">Lanier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Corren</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Lumry</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Liu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Fowler‐Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lanier BQ, Corren J, Lumry W, Liu J, Fowler‐Taylor A et al. Omalizumab is effective in the long‐term control of severe allergic asthma. Ann. Allergy Asthma Immunol. 2003; 91: 154–9.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>154</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Ann. Allergy Asthma Immunol.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>154</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Omalizumab, anti‐IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Busse</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Corren</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BQ</namePart><namePart type="family">Lanier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">McAlary</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Fowler‐Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Busse W, Corren J, Lanier BQ, McAlary M, Fowler‐Taylor A et al. Omalizumab, anti‐IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 2001; 108: 184–90.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>184</start><end>90</end></extent></part><relatedItem type="host"><titleInfo><title>J. Allergy Clin. Immunol.</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>184</start><end>90</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Treatment of allergic asthma with monoclonal anti‐IgE antibody</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Milgrom</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RB</namePart><namePart type="family">Fick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JQ</namePart><namePart type="family">Su</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Reimann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RK</namePart><namePart type="family">Bush</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK et al. Treatment of allergic asthma with monoclonal anti‐IgE antibody. rhuMAb‐E25 Study Group. N. Engl. J. Med. 1999; 341: 1966–73.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>341</number></detail><extent unit="pages"><start>1966</start><end>73</end></extent></part><relatedItem type="host"><titleInfo><title>N. Engl. J. Med.</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>341</number></detail><extent unit="pages"><start>1966</start><end>73</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Omalizumab, a recombinant humanized anti‐IgE antibody, reduces asthma‐related emergency room visits and hospitalizations in patients with allergic asthma</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Corren</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Casale</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Deniz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ashby</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti‐IgE antibody, reduces asthma‐related emergency room visits and hospitalizations in patients with allergic asthma. J. Allergy Clin. Immunol. 2003; 111: 87–90.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>87</start><end>90</end></extent></part><relatedItem type="host"><titleInfo><title>J. Allergy Clin. Immunol.</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>111</number></detail><extent unit="pages"><start>87</start><end>90</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Predicting response to omalizumab, an anti‐IgE antibody, in patients with allergic asthma</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Bousquet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Wenzel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Holgate</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Lumry</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Freeman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P et al. Predicting response to omalizumab, an anti‐IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378–86.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1378</start><end>86</end></extent></part><relatedItem type="host"><titleInfo><title>Chest</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1378</start><end>86</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>The anti‐IgE antibody omalizumab improves asthma‐related quality of life in patients with allergic asthma</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Buhl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Hanf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Soler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Bensch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Wolfe</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Buhl R, Hanf G, Soler M, Bensch G, Wolfe J et al. The anti‐IgE antibody omalizumab improves asthma‐related quality of life in patients with allergic asthma. Eur. Respir. J. 2002; 20: 1088–94.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1088</start><end>94</end></extent></part><relatedItem type="host"><titleInfo><title>Eur. Respir. J.</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>1088</start><end>94</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Anti‐IgE for chronic asthma in adults and children</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Walker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Monteil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Phelan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Lasserson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Walters</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walker S, Monteil M, Phelan K, Lasserson T, Walters E. Anti‐IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2004; (3): CD003559.</note><part><date>2004</date><detail type="issue"><caption>no.</caption><number>3</number></detail></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst. Rev.</title></titleInfo><part><date>2004</date><detail type="issue"><caption>no.</caption><number>3</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Does Anti‐IgE therapy help in asthma. Efficacy and controversies</title></titleInfo><name type="personal"><namePart type="given">PC</namePart><namePart type="family">Avila</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Avila PC. Does Anti‐IgE therapy help in asthma. Efficacy and controversies. Annu. Rev. Med. 2007; 58: 185–203.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>185</start><end>203</end></extent></part><relatedItem type="host"><titleInfo><title>Annu. Rev. Med.</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>185</start><end>203</end></extent></part></relatedItem></relatedItem><identifier type="istex">F30D2E183BDBBC35E40562F8BDF850AB2ECC0932</identifier><identifier type="ark">ark:/67375/WNG-7QGVFDV9-J</identifier><identifier type="DOI">10.1111/j.1440-1843.2007.01017.x</identifier><identifier type="ArticleID">RESP1017</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7QGVFDV9-J/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002365 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002365 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F30D2E183BDBBC35E40562F8BDF850AB2ECC0932
|texte= Omalizumab (Xolair) in patients with steroid‐resistant asthma: Lessons to be learnt
}}
| This area was generated with Dilib version V0.6.33. |  |